REG - Kanabo Group PLC - Board Changes

KanaboAnnouncement

22/03/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220322:nRSV5110Fa&default-theme=true

RNS Number : 5110F  Kanabo Group PLC  22 March 2022

Kanabo Group Plc

("Kanabo" or the "Company")

 

Board Changes

 

 

Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis Company
focussing on the development and distribution of cannabis-derived products for
medical patients and wellness CBD consumers, announces the appointment of Gil
Efron to the Company's Board as a non-executive director, with effect from
March 21(st,) 2022.

 

Kanabo's Audit Committee is currently chaired by Uzi Danino, who will retire
as a Non-Executive Director to focus on his other business interests. Gil will
take over as chair of the Audit Committee following Uzi's retirement.

 

Gil is serving as President and Chief Financial Officer of NASDAQ and TASE
dual-listed Purple Biotech Ltd., a clinical-stage company (PPBT) since June
2021, having previously held the position of Deputy Chief Executive Officer
and Chief Financial Officer from October 2018. Prior to his current tenure at
Purple Biotech, Gil served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and
TASE dual-listed plasma-derived protein therapeutics company between
2011-2017.

 

Commenting on the appointment Avihu Tamir, founder and CEO of Kanabo, said:
"We are delighted to welcome Gil to the board. His wealth of experience in the
capital market will be an excellent addition to Kanabo's Board, as well as his
vast business and financial management experience. The Board and I would like
to thank Uzi for his tireless dedication in bringing Kanabo to the listed
market in the UK. We have benefited greatly from his experience and counsel
over the past 3.5 years and wish him well in all his future endeavours."

 

 

There are no details to be disclosed under paragraphs 9.6.13 (2) to (6) of the
Listing Rules.

 

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.]

 

 

For further information, please visit http://www.kanabogroup.com/ or contact
the following:

 Kanabo Group Plc                            Via Vox Markets
 Avihu Tamir, CEO
 Peterhouse Capital Ltd (Financial Adviser)  Tel: +44 (0)20 7469 0930
 Eran Zucker / Lauren Riley
 Peterhouse Capital Ltd (Corporate Broker)   Tel: +44 (0)20 7469 0930
 Lucy Williams / Charles Goodfellow
 Vox Markets (Investor Relations)            KanaboGroup@voxmarkets.co.uk
 Kat Perez                                   kperez@voxmarkets.co.uk

 

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry
to improve the well-being of millions of people around the world by providing
a better alternative to the smoking of medicinal cannabis flowers. Kanabo,
which was the first medicinal cannabis company to IPO on London Stock
Exchange, has a focus on the distribution of cannabis-derived products for
medical patients and non-THC products for CBD consumers. It has conducted
extensive Research & Development to produce high-quality cannabis extract
formulas, innovative medical-grade vaporizers, and various non-smoking
consumption solutions. Kanabo sells a range of medical cannabis products and
wellness CBD products in the Primary Markets, including its VapePod, which
delivers a metered dose with every inhalation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAXDFAFXAEFA